Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents

Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents

Synthesis and anti-hepatitis C virus (anti-HCV) effects of certain 3-amino-2-hydroxy-propoxy isoflavone derivatives, <b>6a</b>⁻<b>i</b>, were described. The known 3-(3,4-dimethoxyphenyl)-7-(oxiran-2-ylmethoxy)-4<i>H</i>-chromen-4-one (<b>5</b>...

Full description

Bibliographic Details
Main Authors:	Jin-Ching Lee, Chun-Kuang Lin, Chin-Kai Tseng, Yeh-Long Chen, Cherng-Chyi Tzeng, Chih-Hua Tseng
Format:	Article
Language:	English
Published:	MDPI AG 2018-11-01
Series:	Molecules
Subjects:	3-amino-2-hydroxypropoxyisoflavones ribavirin hepatitis C virus cytotoxicity
Online Access:	https://www.mdpi.com/1420-3049/23/11/2863

Similar Items

Conventional Versus Pegylated Interferons in Treatment of HCV Patients
by: M Amirbigi, et al.
Published: (2012-04-01)

A Practical Approach to Managing Patients with HCV Infection
Published: (2006-04-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Discovery of 3-Arylquinoxaline Derivatives as Potential Anti-Dengue Virus Agents
by: Chih-Hua Tseng, et al.
Published: (2019-09-01)

Current and future treatment options for HCV
by: Bernd Kronenberger, et al.
Published: (2009-04-01)

HBsAg loss with HBsAg/anti-HBs seroconversion and non-detectable HCV-RNA in a patient with chronic HBV e-minus/HCV hepatitis treated with two cycles of antiviral therapy
by: Antonio Salvio, et al.
Published: (2012-01-01)

Experimental models for hepatitis C virus (HCV): New opportunities for combating hepatitis C
by: Karina del Carmen Trujillo-Murillo, Ph.D., et al.
Published: (2004-04-01)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
by: Gupta Rahul, et al.
Published: (2012-03-01)

Treatment for recurrent HCV infection after liver transplantation for final stages of chronic hepatitis С
by: V. E. Syutkin, et al.
Published: (2018-08-01)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01)

Cryoglobulinemic glomerulonephritis: an extrahepatic manifestation of hepatitis C virus (HCV) infection
by: Giovanni Garini, et al.
Published: (2007-12-01)

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
by: K.S. Abdelkawy, et al.
Published: (2020-01-01)

Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C
by: Tseng CW, et al.
Published: (2016-03-01)

Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy
by: Giuliano Ramadori, et al.
Published: (2018-03-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre
by: Maciej Bura, et al.
Published: (2012-06-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
by: Liu Jun-Ying, et al.
Published: (2012-09-01)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
by: Fabio Conti, et al.
Published: (2014-03-01)

Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK)
by: Ahmad Bashir, et al.
Published: (2012-01-01)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
by: Suzanne Tavitian, et al.
Published: (2015-08-01)

Physiopathologie du traitement de l'hépatite chronique C par les interférons, la ribavirine et les inhibiteurs spécifiques
by: Hézode, Christophe
Published: (2011)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
by: Artico Simara, et al.
Published: (2012-12-01)

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
by: Woo Jin Chung
Published: (2012-09-01)

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C
by: Bilgehan AYGEN, et al.
Published: (2004-09-01)

Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C
by: Nathália Delvaux, et al.
Published: (2015-08-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
by: Suh Yoon Yang, et al.
Published: (2015-06-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases
by: CAI Shaoping
Published: (2014-01-01)

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
by: Carlo Smirne, et al.
Published: (2021-08-01)

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
by: Hussien Ahmed, et al.
Published: (2018-01-01)

Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study
by: Yunus Gürbüz, et al.
Published: (2016-02-01)

Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report
by: Adriano M. Pellicelli, M.D., et al.
Published: (2012-11-01)

Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan
by: Yu-Kang Chang, et al.
Published: (2019-04-01)

A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection
by: Yutaka Kishida, et al.
Published: (2016-03-01)

Cannot write session to /tmp/vufind_sessions/sess_co4rk5164ng144j6cpv4lsu85n